Home/Filings/4/0001209191-18-035407
4//SEC Filing

MECHEM KRISTINE C. 4

Accession 0001209191-18-035407

CIK 0001642380other

Filed

Jun 3, 8:00 PM ET

Accepted

Jun 4, 8:55 PM ET

Size

9.8 KB

Accession

0001209191-18-035407

Insider Transaction Report

Form 4
Period: 2018-05-23
MECHEM KRISTINE C.
VP of Marketing
Transactions
  • Award

    Option to Purchase Common Stock

    2018-05-23+125,000125,000 total
    Exercise: $2.35Exp: 2028-05-22Common Stock (125,000 underlying)
Holdings
  • Option to Purchase Common Stock

    Exercise: $3.06Exp: 2026-02-15Common Stock (60,000 underlying)
    60,000
  • Option to Purchase Common Stock

    Exercise: $3.16Exp: 2025-08-03Common Stock (100,000 underlying)
    100,000
  • Option to Purchase Common Stock

    Exercise: $4.70Exp: 2027-02-16Common Stock (67,500 underlying)
    67,500
Footnotes (4)
  • [F1]These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
  • [F2]One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
  • [F3]One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
  • [F4]One quarter of the options vested on August 3, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.

Issuer

OncoCyte Corp

CIK 0001642380

Entity typeother

Related Parties

1
  • filerCIK 0001662454

Filing Metadata

Form type
4
Filed
Jun 3, 8:00 PM ET
Accepted
Jun 4, 8:55 PM ET
Size
9.8 KB